Interim Report for Ortivus AB (publ) for the period January – June 2025
2025-08-26 08:30
A significant impact for the patient and for the healthcare system as a whole, including its costs.
April-June 2025
- Net sales increased by 11% to SEK 19.7 (17.7) million.
- Gross margin increased to 51% (30%).
- EBITDA amounted to SEK -4.7 (-7.7) million.
- Adjusted EBITDA amounted to SEK 0.4 (-7.7) million.
- Net profit after tax amounted to SEK -6.5 (-8.3) million.
- Earnings per share before and after dilution amounted to SEK -0.15 (-0.19).
January-June 2025
- Net sales decreased by 5% and amounted to SEK 37.8 (39.7) million.
- The gross margin increased to 46 (36)%.
- EBITDA amounted to SEK -6.1 (-9.1) million.
- Adjusted EBITDA amounted to SEK -1.0 (-9.1) million.
- Net profit after tax amounted to SEK -8.9 (-10.5) million.
- Earnings per share after tax before and after dilution amounted to SEK -0.20 (-0.24).
Significant events during and after the end of the period
- Ortivus’ annual International User Forum was held in Birmingham at the end of April, with attendance from all international customers. Participants received updates on iOS, cloud-based solutions, cybersecurity, and data capture.
- ST Engineering in Singapore extended its agreement in April for the delivery of Ortivus MobiMed ePR for a further two years, with an order value of SEK 2.9 million.
- Northern Ireland Ambulance Service extended its contract for the delivery of Ortivus MobiMed ePR for a further two years, with an order value of SEK 5.5 million.
- Tervisekassa, Telia Eesti AS and Ortivus reached an agreement to terminate an ongoing project. Ortivus’ role in the project was to deliver the MobiMed ePR as a SaaS-based solution. The impact on earnings in Q2 2025 amounted to SEK -5.1 million.
- South Western Ambulance Service NHS Foundation Trust extended its contract for the delivery of Ortivus MobiMed ePR for a further two years, with an order value of SEK 27.7 million.
- Following the end of the quarter, South Central Ambulance NHS Foundation Trust chose to extend its contract for the delivery of Ortivus MobiMed ePR for a further two years, with an order value of SEK 16.8 million.
- On 25 August, the Board of Directors convened an extraordinary general meeting, proposing a fully guaranteed rights issue of approximately SEK 54 million.